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Abstract
Introduction: The aim of the study was to describe the levels of circulating monocyte/macrophage pro-inflammatory
cytokines (TNF-α, IL-1β, IL-6, and IL-8) and an anti-inflammatory cytokine (IL-10) in inflammatory bowel disease (IBD)
and colorectal cancer (CRC) patients and healthy controls. 
Materials and Methods: The study was conducted on 15 healthy individuals, 20 patients with ulcerative colitis (UC), 12 with
Crohn’s disease (CD), and 15 with CRC (Dukes’ stage B). Blood serum cytokine levels were measured by ELISA. 
Results: The patients with UC had significantly higher levels of the pro-inflammatory cytokines and of circulating IL-10 than
the healthy controls. The patients with CD and CRC had the same specific pattern of serum cytokines of significantly ele-
vated levels of the pro-inflammatory cytokines, but the IL-10 levels were within the range found in the healthy individuals. 
Conclusions: Thus our results demonstrate that both IBD and CRC are linked with an intensified production of a wide array
of monocyte/macrophage pro-inflammatory cytokines which is not accompanied by elevated levels of circulating IL-10,
except for its insufficiently inhibitory elevation in UC patients.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are
inflammatory bowel diseases (IBDs) characterized by
chronic relapsing inflammation of the gut that ultimate-
ly leads to destruction of the intestinal tissue. Although
their etiology is not yet fully known, the initiation and
aggravation of the inflammatory process seem to be due
to a dysregulated immune responses with a parallel
increase in the expressions of pro-inflammatory
cytokines, including tumor necrosis factor (TNF)-α,
interleukin (IL)-1β, IL-6, and IL-8 (Hyun and Mayer
2006; Shih and Targan 2008). At the same time, defi-
ciency of IL-10, an anti-inflammatory cytokine, seems to
contribute to persistent intestinal inflammation (Li and
He 2004; Shih and Targan 2008). Clinical reports have
well document an increased risk of intestinal cancer in
UC and CD patients (Askling et al. 2001; Eaden et al.
2001; Jess et al. 2005). However, it is still unclear if any
relationship exists between pro-inflammatory cytokine
and IL-10 expression in IBD and the development of
intestinal neoplasms. 
Considering the above, the aim of the present study
was to describe the levels of circulating pro-inflammato-
ry cytokines (TNF-α, IL-1β, IL-6, and IL-8) and IL-10 in
IBD and colorectal cancer (CRC) patients.
MATERIALS AND METHODS
Patients 
The study was conducted on 47 patients hospitalized
at the Department of General, Gastroenterological,
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and Endocrinological Surgery, University of Medical
Sciences in Poznañ, Poland, and 15 healthy subjects
representing the control group. Employing standard
clinical, radiological, endoscopic, and histopathological
criteria (except for histopathological diagnosis in the
healthy subjects), four study groups were distinguished.
Group 1 included the 15 control healthy volunteers (6
men and 9 women, age range: 25–63, mean: 42.5 years)
who manifested no organic disease, including normal
endoscopy. No patients with post-infectious colitis were
included. Group 2 included 20 patients (10 men and 10
women, age range: 21–50, mean: 39.5 years) with active
UC with an average duration of 5.9 years (range: 0.5–25
years) and activity estimated using the histological scor-
ing system according to Geboes et al. (Geboes et al.
2000) amounting to 4.3 in 14 patients and 5.3 in the
remaining 6 patients. Group 3 included 12 patients (6
men and 6 women, age range: 15–42, mean: 28.6 years)
with active CD with an average duration of 4.2 years
(range: 0.5–34 years) and an average clinical activity
CDAI score of over 150 points (Best et al. 1976). Group
4 included 15 patients (5 men and 10 women, age
range: 40–69 years, mean: 60.7 years) with an average
duration of symptoms of 0.66 years (range: 0.5–0.8
year). In the CD patients, stage B (Dukes’ classifica-
tion) of CRC was diagnosed, with no infiltration of
regional organs and no metastasis. The patient groups
showed no signs of infection. The standard surgical
treatment was applied in all the patients. The IBD
patients were receiving steroids (prednisone and sul-
fasalazin). However, in the preoperative period the
drug doses were reduced to discontinue them within
7–10 days before the planned operative procedure.
Venous blood was sampled from the patients 24
h before surgical treatment. It was the centrifuged at
1500×g for 15 min at room temperature and, the serum
was collected and frozen (–80°C). The cytokine levels
were determined after collection of all the sera. All the
research protocols were reviewed and approved by the
ethics committee of the university.
Measurement of cytokines 
The levels of TNF-α, IL-1β, IL-6, IL-8, and IL-10
were established in the sera of all the participants by
ELISA, using the Quantikine kit for the detection of 
IL-8 and Quantikine HS (both R&D Systems,
Abingdon, UK) for the detection of the remaining
cytokines. The minimum levels detectable using the
ELISA kits were 0.106 pg/ml for TNF-α, 0.057 pg/ml for
IL-1β, 0.039 pg/ml for IL-6, 3.5 pg/ml for IL-8, and 0.5
pg/ml for IL-10. The tests were conducted according to
the manufacturer’s instructions. The optical density was
read using a microplate reader (bioMerieux Reader
250) at λ=450 nm in the IL-8 assay and λ=490 nm for
the remaining cytokines. The cytokine content of each
serum was tested three times and the results expressed
in pg/ml are the means of these.
Statistical analysis 
The results were expressed as the mean±standard
deviation (SD). The Mann-Whitney test was used to
evaluate the significance of differences between the
groups at a p<0.05 level of significance.
RESULTS
The levels of TNF-α, IL-1β, IL-6, IL-8, and IL-10
detected in the sera of the healthy individuals (group 1)
represented the normal values with which the levels
obtained in the patient groups were compared. The lev-
els are presented in Table 1 and Fig. 1.
The UC patients had significantly higher levels of
TNF-α, IL-1β, IL-6, IL-8, and IL-10 than the control
group.
The CD patients also had significantly higher levels
of TNF-α, IL-1β, IL-6, and IL-8 than the control group,
but the level of IL-10 was not significantly different from
the normal value. The UC patients had significantly
lower levels of TNF-α and IL-8 and significantly higher
levels of IL-10 than the CD patients (Table 2).
The CRC patients had significantly higher levels of
TNF-α, IL-1β, IL-6, and IL-8 than the control group,
but the level of IL-10 was not significantly different from
the normal value. The CRC patients had significantly
higher levels of TNF-α and IL-8 and a significantly
lower level of IL-10 than the UC patients. The cytokine
levels in the CRC and CD patients showed no signifi-
cant differences (Table 2).
DISCUSSION
This study analyzed the levels of the circulating pro-
-inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8
and the anti-inflammatory cytokine IL-10 in patients
with IBD and patients with CRC. The first set of
cytokines promotes inflammatory host reactions in
response to various damaging agents, including micro-
bial products (Oppenheim and Neta 1994). Antigen-
-presenting cells, mainly monocytes/macrophages, are
their principal source and therefore manifest a broad
immunostimulatory activity (Medzhitov and Janeway
1997). IL-10, produced mainly by T helper lymphocytes
(Th) and regulatory T cells (TReg), exerts a strong sup-
pressive role on the production of pro-inflammatory
cytokines and a regulatory role on Th immune reactions
(Mosmann and Sad 1996; Pestka et al. 2004; Taylor et
al. 2006). 
In this study, elevated levels of the monocy-
te/macrophage pro-inflammatory cytokines were detect-
ed in the sera of patients with either UC or CD. The
results point to a continuous activation of monocy-
tes/macrophages in the course of IBD and correspond
to other results (Hyun and Mayer 2006; Rogler and
Andus 1998). Nevertheless, the causal factors beyond
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the activation of the cells are incompletely understood,
although experiments on animal models provide evi-
dence for the importance of antigens of commensal bac-
teria in stimulation of the mucosal immune system
(Rennick and Fort 2000; Sartor 2004). Mycobacterium
avium subspecies paratuberculosis is also currently sug-
gested to determine bacterial signals which induce the
pro-inflammatory response in CD (Bull et al. 2003;
Szkaradkiewicz et al. 2007). Monocyte/macrophage acti-
vation is also augmented by the Th1 response, expressed
by the elevated secretion of interferon-γ and IL-12 in
patients with CD (Autschbach et al. 2002; Plevy et al.
1997). 
The involvement of Th17 lymphocytes, which pro-
duce IL-6/IL-17, has been demonstrated in the develop-
ment the inflammatory process in CD (Fujino et al.
2003; Yen et al. 2006). On the other hand, in UC the
inflammatory response seems to be dominated by Th2
lymphocytes, which secrete high amounts of IL-5 and
IL-13 (Fuss et al. 2004). The increase in circulating 
IL-10 level in UC demonstrated in this study, in turn,
seems to result from the activity of TReg cells. This con-
clusion can be backed up by results documenting the
expression of transforming growth factor-β1, which is
also released by TReg cells, in patients with UC (Taylor
et al. 2006; Wierciñska-Drapa³o et al. 2001). Thus it
seems possible that the induced TReg cells suppressing
an immune response cause the inflammation in UC to
be more superficial than the transmural pathological
process in CD. Nevertheless, in the presented results,
except for TNF-α and IL-8, no significant differences
were detected between the elevated concentrations of
the pro-inflammatory cytokines in the sera of the
patients with UC or CD. These data may indicate that
the relatively low production of IL-10 in UC is insuffi-
cient to inhibit the secretory activity of mono-
cytes/macrophages. Thus, the currently well-established
TReg-Th cell interactions (Groux et al. 1997; Taylor et al.
2006) may be of decisive significance for the course of
IBD.
In the sera of the patients with CRC, a significant
elevation was also noted in the levels of the pro-inflam-
matory cytokines TNF-α, IL-6, and IL-8, consistent with
the results earlier presented by other authors (Belluco
et al. 2000; Kamiñska et al. 2000). Moreover, the levels
of the cytokines in the patients with CRC and those with
CD showed no significant differences. In parallel, the
levels of circulating IL-10 in CRC and CD were within
the normal range. These data, presented for the first
time in this study, document the same specific pattern of
the serum cytokine levels in patients with CRC or CD
characterized by the stimulated production of mono-
cyte/macrophage pro-inflammatory cytokines in the
presence of normal circulating levels of IL-10. Already
published data have presented contradictory results
Table 1. Cytokine levels (TNF-α, IL-1β, IL-6, IL-8, IL-10) in sera of the healthy subjects and patients with UC, CD, or CRC
Studied groups Means values in pg/ml ±SD and range in parentheses [median values]
TNF-α IL-1β IL-6 IL-8 IL-10
Healthy subjects 0.61±0.28 0.12±0.10 1.59±0.90 9.77±7.65 1.35±0.96
(group 1, n=15) (0.10–1.0)  (0.0–0.2) (0.6–3.2) (0.0–22.1) (0.0–2.8)
[06] [0.16] [1.18] [9.9] [1.65]
Patients with UC 1.18±0.73* 1.35±1.21* 8.63±2.14* 31.84±12.97* 4.40±1.55*
(group 2, n=20) (0.1–2.5) (0.4–4.6) (4.8–12.8) (14.6–61.3) (2.0–6.7)
[1.1] [0.86] [8.6] [28.0] [4.28]
Patients with CD 3.12±2.42* 0.94±0.84* 8.24±1.75* 53.70±41.52* 2.16±1.46
(group 3, n=12) (1.5–7.8) (0.3–2.8) (5.8–10.8) (28.0–149.8) (0.0–3.9)
[1.875] [0.415] [8.7] [37.6] [2.5]
Patients with CRC 1.9±1.00* 1.44±0.98* 10.51±3.33* 49.74±31.67* 1.99±1.19
(group 4, n=15) (0.9–3.8) (0.4–3.2) (7.5–18.0) (29.0–168.0) (0.24–4.2)
[1.51] [1.16] [9.9] [38.0] [2.0]
*Significant difference in cytokine level between the patients and healthy subjects.
Fig. 1. Serum cytokine levels in studied groups of patients.
Table 2. Statistical comparison of cytokine levels in patients
with UC, CD, and CRC
Examined p  (Mann-Whitney test)
groups TNF-α IL-1β IL-6 IL-8 IL-10
UC vs. CD <0.05 0.1571 0.9222 <0.05 <0.05
UC vs. CRC <0.05 0.5157 0.0770 <0.05 <0.05
CD vs. CRC 0.1020 0.0645 0.0639 0.7407 0.6255
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related to preoperative serum IL-10 levels in CRC
patients, pointing to a relationship between higher 
IL-10 levels and an inoperable tumor (Galizia et al.
2002; Kamiñska et al. 2000). On the other hand, our
study was conducted in patients with operable CRC
(Dukes’ stage B), which may explain the contradictions.
Thus our results demonstrate that both IBD and
operable CRC are accompanied by augmented produc-
tion of a wide array of monocyte/macrophage pro-
-inflammatory cytokines. The level of circulating IL-10,
in turn, remained within the range of normal values,
except for its elevated level in UC which, nevertheless,
was not sufficient to inhibit the secretory activity of
monocytes/macrophages. Disturbed equilibrium
between pro- and anti-inflammatory cytokine responses
seems to play a significant role in the pathogeneses of
IBD and CRC.
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